Abstract
A series of clinical and experimental observations support the notion that cerebral opioid peptides may play a role in mood regulation and could be involved in the pathophysiology of affective disorders and the action of antimanic and anti-depressant treatments. The oldest evidence for this hypothesis is that for many years, before the advent of tricyclic antidepressants, the ‘opium cure’ was used with some beneficial effect in the treatment of depressed patients in spite of obvious side-effects. Indeed, the three families of opioid peptides and their receptors are particularly abundant in several limbic structures believed to be involved in mood regulation (Cuello, 1983). Stimulation of these receptors by opiates has been known for centuries to have hedonic actions in humans, eliciting a dream-like euphoria, for which presumably they have been self-administered. It has even been hypothetised that opiate-dependent individuals become addicted because opiates relieve their depressive symptoms (McLellan et al., 1982). A slight antidepressant activity of morphine has been reported (Extein et al., 1981). Also, buprenorphine, a partial agonist at opiate receptors, was recently shown to ameliorate symptoms in depressed patients (Emrich et al., 1982). Similar observations were made following the intravenous administration of β-endorphin (Kline et al., 1977; Angst et al., 1977; Gerner et al., 1980) but could not be replicated in another study (Pickar et al., 1981).
Preview
Unable to display preview. Download preview PDF.
References
Algeri, S., Altstein, M., De Simone, M., and Guardabasso, G.M. (1981). Eur. J. Pharmacol., 74, 207–9.
Algeri, S., Brunello, N., Calderini, G., and Consolazione, A. (1978). In Costa, E., and Trabucchi, M. (eds.), Advances in Biochemical Psychopharmacology, vol. 18. Raven, New York, 199–210.
Angst, J., Autenrieth, V., Brem, F., Kokkou, M., Meyer, H., Stassen, H.H., and Storck, U. (1979). In Usdin, E., and Bunney, W.E. (eds.), Endorphins in Neutral Health Research. Macmillan, London, 518–28.
Arbilla, S., and Langer, S.Z. (1978). Nature, 271, 559–60.
Attila, L.M.J., and Ahtee, L. (1983). Supplement to Progress in Neuropsychopharma-cology and Biological Psychiatry, 25, 74.
Ben Natan, L.,Chaillet,P., Lecomte, J.-M., Marcais, H., Uchida, G., and Costentin, J. (1984). Eur. J. Pharmacol., 97, 301–4.
Bird, S.J., and Kuhar, M.J. (1977). Brain Res., 122, 523–33.
Bloom, A.S., Dewey, W.L., Harris, L.S., and Brosius, K.K. (1976). J. Pharmacol. Exp. Ther., 198, 33–41.
Carenzi, A., Frigeni, V., and Delia Bella, D. (1978). In Costa, E., and Trabucchi, M. (eds.), The Endorphins, vol. 3. Raven, New York, 265–70.
Cuello, A.C. (1983). Brit. Med. Bull, 39, 11–16.
De Felipe, M.C., De Ceballos, M.L., Gie, C., and Fueutes, J.A. (1985). Eur. J. Pharmacol., 112, 119–22.
De La Baume, S., Yi, C.C., Schwartz, J.-C., Chaillet, P., Marcais-Collado, H., and Costentin, J. (1983). Neuroscience, 8, 143–51.
Devoize, J.L., Rigal, A., Eschalier, A., and Trolese, J.F. (1982) Eur. J. Pharmacol., 78, 229–32.
Emrich, H.M., Vogt, P., and Herz, A. (1982). Ann. N. Y. Acad. Sci., 398, 108–12.
Extein, I., Pickar, D., Gold, M.S., Gold, P.W., Pottash, A.L.C., Sweeney, D.R., Ross, R.J., Rebard, R., Martin, D., and Goodwin, F.K. (1981). Pharmacol. Bull, 17, 29–33.
Gerner, R.H., Catlin, D.H., Gorelick, D.A., Huie, K.K., and Li, C.H. (1980). Arch. Gen. Psychiatry, 37, 642–7.
Gillin, J.-C., Hong, J.S., Yang, H.Y.T., and Costa, E. (1978). Proc. Nati Acad. Sci. USA, 75, 1991–3.
Giros, B., Gros, C., Solhonne, B., and Schwartz, J.-C. (1986a). Mol. Pharmacol., 29, 281–7.
Giros, B., Llorens-Cortes, C., Gros, C., and Schwartz, J.-C. (1986b). Peptides, 7, 669–78.
Gros, C., Giros, B., and Schwartz, J.-C. (1985). Biochemistry, 24, 2179–85.
Kalivas, P.W., and Richardson-Carlson, R. (1986). Am. J. Physiol., 251, R243–9.
Kline, N.S., Li, C.H., Lehmann, H.E., Lajtha, A., Laski, E., and Cooper, T.B. (1977). Arch. Gen. Psych., 34, 1111–3.
Kotf, J., Bunney, B.S., and Aghajanian, G.K. (1974). Eur. J. Pharmacol., 25, 165–9.
Lecomte, J.-M., Costentin, J., Vlaiculescu, A., Chaillet, P., Marcais-Collado, H., Llorens-Cortes, C., Leboyer, M. and Schwartz, J.-C. (1986). J. Pharmacol. Exp. Ther., 237, 937–44.
Lee, R., and Spencer, P.S.J. (1977). J. Int. Med. Res., 5, 146–56.
Lindström, L.H., Widerlof, E., Gunne, L.M., Wahlstrom, A., and Terenius, L. (1978), Acta Psychiatr. Scand., 51, 153–64.
Llorens-Cortes, C., Gros, C., and Schwartz, J.-C. (1985b). Eur. J. Pharmacol, 119, 183–91.
Llorens-Cortes, C., Gros, C., and Schwartz, J.-C. (1986). Proc. Natl Acad. Sci. USA, 83, 6226–30.
Llorens, C., Martres, M.P., Baudry, M., and Schwartz, J.-C. (1978), Nature, 274, 603–5.
Llorens-Cortes, C., Schwartz, J.-C., and Gros, C. (1985a). FEBS Lett., 189, 325–8.
Malfroy, B., Swerts, J.P., Guyon, A., Roques, B.P., and Schwartz, J.-C. (1978). Nature, 276, 523–6.
McLellan, A.T., Woody, G.E., Evans, B.D., and O’Brien, C.P. (1982). Ann. N. Y. Acad. Sci., 398, 65–78.
Montel, H., Starke, K., and Taube, H.D. (1975). Naunyn Schmiedelberg’s Arch. Pharmacol, 288, 427.
Naber, D., Pickar, D., Post, R.M., Van Kämmen, D.P., Waters, R.N., Ballinger, J.C., Goodwin, F.K., and Bunney, W.E.J. (1981). Am. J. Psychiatry, 138, 1457–62.
Pert, A. (1978). In Van Ree, J.M., and Terenius, L. (eds.), Characteristics and Functions of Opioids. Elsevier, Amsterdam, 389–99.
Pert, C.B., Kuhar,M. J., and Snyder, S.H. (1976). Proc. Natl Acad. Sci., USA, 73, 3729–33.
Pickar, D., Davis, G.C., Schulz, S.C., Extein, I., Wagner, R., Naber, D., Gold, P.W., Van Kammen, D.P., Goodwin, F.K., Wyatt, R.J., Li, Ch., and Bunney, W.E. (1981). Am. J. Psychiatry, 138, 160–6.
Pickar, D., Vartanian, F., Bunney, W.E., Maier, H.D., Gastpar, M.T., Prakash, R., Setthi, B.B., Belgaer, B., Tsultulkausa, M., Junghunz, G., Nedopil, T.N., Verhoeven, W., and Van Praag, H. (1982). Arch. Gen. Psychiatry, 39, 313–9.
Pollard, H., Llorens-Cortes, C., and Schwartz, J.-C. (1977). Nature, 268, 745–7.
Porsolt, R.D., Bertin, A., and Jalfre, M. (1977). Arch. Int. Pharmacodyn. Ther., 229, 327–35.
Reisine, T.D., Nagy, A.L., Beaumont, K., Fibiger, H.I., and Yamamura, H.I. (1979). Brain Res., 177, 241–5.
Sabol, S.L., Yoshikawa, K., and Hong, J.S. (1983). Biochem. Biophys. Res. Commun., 113, 391–9.
Schechter, M.D., and Chance, W.T. (1979). Eur. J. Pharmacol, 60, 139–43.
Schwartz, J.-C., Costentin, J., and Lecomte, J.-M. (1985). Trends Pharmacol. Sci., 6, 472–6.
Schwartz, J.-C., De La Baume, S., Yi, C.C., Chaillet, P., Marcais-Collado, H., and Costentin, J. (1982). Prog. Neuro. Psych., 6, 665–71.
Schwartz, J.-C., Malfroy, B., and De La Baume, S. (1981). Life Sci., 29, 1715–40.
Sivam, S.P., Strunk, C., Smith, D.R., and Hong, J.S. (1986). Mol Pharmacol, 30, 186–91.
Smith, C B., Sheldon, M.I., Bednarczyk, J.H., and Villarreal, J.E. (1972). J. Pharmacol Exp. Ther., 180, 547–57.
Staunton, D.A., Deyo, S.N., Shoemaker, W.J., Etterberg, A., and Bloom, F.E. (1982). Life Sel, 39, 1837–40.
Sulser, F., Ventulani, J., and Mobly, P.L. (1978). Biochem. Pharmacol, 27, 257–61.
Tanaka, M., Kohno, Y., Nakagawa, R., Ida, Y., Imori, K., Hoaki, Y., Tsuda, A., and Nagakai, N. (1982). Life Sci., 30, 1663–9.
Wood, P.L. (1982). Eur. J. Pharmacol, 82, 119–20.
Yarbrough, G.G., Buxbaum, D.M., and Sander-Bush, E. (1973). J. Pharmacol Exp. Ther., 185, 328–35.
Young, W.S., Bird, S.J., and Kuhar, M.J. (1977). Brain Res., 129, 366–70.
Editor information
Editors and Affiliations
Copyright information
© 1988 The Editors and the Contributors
About this chapter
Cite this chapter
Schwartz, JC., van Amsterdam, J., Llorens-Cortes, C., Costentin, J. (1988). Endogenous Enkephalins, Depression and Antidepressants. In: Briley, M., Fillion, G. (eds) New Concepts in Depression. Palgrave, London. https://doi.org/10.1007/978-1-349-09506-3_23
Download citation
DOI: https://doi.org/10.1007/978-1-349-09506-3_23
Publisher Name: Palgrave, London
Print ISBN: 978-1-349-09508-7
Online ISBN: 978-1-349-09506-3
eBook Packages: MedicineMedicine (R0)